Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review

Dec 13, 2022Clinical epidemiology

Effectiveness and Safety of Liraglutide and Semaglutide for Weight Loss in Overweight or Obese People

AI simplified

Abstract

Semaglutide 2.4 mg resulted in an average weight loss of -12.47 kg in individuals with obesity or overweight.

  • Semaglutide 2.4 mg demonstrated the highest weight loss compared to liraglutide 3.0 mg (-5.24 kg), semaglutide 1.0 mg (-3.74 kg), and liraglutide 1.8 mg (-3.29 kg).
  • All treatments were more effective than placebo in reducing HbA1c levels, with semaglutide 2.4 mg showing the greatest reduction (MD=-1.48%).
  • The incidence of total adverse events was highest for semaglutide 2.4 mg, followed by liraglutide 3.0 mg, liraglutide 1.8 mg, and semaglutide 1.0 mg.
  • Serious adverse events were most frequently associated with liraglutide 3.0 mg, followed by liraglutide 1.8 mg, semaglutide 2.4 mg, and semaglutide 1.0 mg.
  • Hypoglycemic events were more common with semaglutide 2.4 mg than with liraglutide 3.0 mg, semaglutide 1.0 mg, and liraglutide 1.8 mg.

AI simplified

Key numbers

-12.47 kg
Weight Loss (kg)
Weight loss compared to placebo.
-1.48%
HbA1c Reduction (%)
Reduction compared to placebo.
2.36
Total Adverse Events Ratio
Odds ratio for total adverse events.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free